Metallic ion-cross-linked polymer of intrinsic microporosity(PIM-1) thin-film composite(TFC) membranes supported on an ultraviolet(UV)-cross-linked porous substrate were fabricated. The UV-cross-linked porous substrat...Metallic ion-cross-linked polymer of intrinsic microporosity(PIM-1) thin-film composite(TFC) membranes supported on an ultraviolet(UV)-cross-linked porous substrate were fabricated. The UV-cross-linked porous substrate was prepared via polymerization-induced phase separation. The PIM-1 TFC membranes were fabricated via a dip-coating procedure. Metallic ion-cross-linked PIM-1 TFC membranes were fabricated by hydrolyzing the PIM-1 TFC membrane in an alkali solution and then cross-linking it in a multivalent metallic ion solution. The pore size and porous structures were evaluated by low-temperature N_2 adsorption–desorption analysis. The membrane structure was investigated by field-emission scanning electron microscopy. The effects of heat treatment and pore-forming additives on the gas permeance of the UV-cross-linked porous substrate are reported. The effects of different pre-coating treatments on the gas permeance of the metallic ion-cross-linked PIM-1 TFC membrane are also discussed. The metallic ion-crosslinked PIM-1 TFC membrane displayed high CO_2/N_2 selectivity(23) and good CO_2 permeance(1058 GPU).展开更多
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (COVID-19) have a substantial burden on health-care systems around the world. This is a ran...Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (COVID-19) have a substantial burden on health-care systems around the world. This is a randomized parallel controlled trial for assessment of the immunogenicity and safety of an inactivated SARS-CoV-2 vaccine, aiming to determine an appropriate vaccination interval of the vaccine for high-risk occupational population.Methods: In an ongoing randomized, parallel, controlled phase IV trial between January and May 2021 in Taiyuan City, Shanxi Province, China, we randomly assigned the airport ground staff and public security officers aged 18 to 59 years to receive two doses of inactivated SARS-CoV-2 vaccine at 14 days, 21 days, or 28 days. The serum neutralizing antibody to live SARS-CoV-2 was performed at baseline and 28 days after immunization. Long-term data are being collected. The primary immunogenicity endpoints were neutralization antibody seroconversion and geometric mean titer (GMT) at 28 days after the second dose. Analysis of variance (ANOVA), chi-square, and logistic regression analysis were used for data analysis.Results: A total of 809 participants underwent randomization and received two doses of injections: 270, 270, 269 in the 0-14, 0-21, and 0-28 vaccination group, respectively. By day 28 after the second injection, SARS-CoV-2 neutralizing antibody of GMT was 98.4 (95%CI: 88.4-108.4) in the 0-14 group, which was significantly lower compared with 134.4 (95%CI: 123.1-145.7) in the 0-21 group (P < 0.001 vs 0-14 group) and 145.5 (95%CI: 131.3-159.6) in the 0-28 group (P < 0.001 vs 0-14 group), resulting in the seroconversion rates to neutralizing antibodies (GMT ≥ 16) of 100.0% for all three groups, respectively. The intention-to-treat (ITT) analysis yielded similar results. All reported adverse reactions were mild.Conclusions: Both a two-dose of inactivated SARS-CoV-2 vaccine at 0-21 days and 0-28 days regimens significantly improved SARS-CoV-2 neutralizing antibody level compared to the 0-14 days regimen in high-risk occupational population, with seroconversion rates of 100.0%.展开更多
基金Supported by the National Natural Science Foundation of China(21506160,21776217)the Science and Technology Plans of Tianjin(16PTSYJC00110)
文摘Metallic ion-cross-linked polymer of intrinsic microporosity(PIM-1) thin-film composite(TFC) membranes supported on an ultraviolet(UV)-cross-linked porous substrate were fabricated. The UV-cross-linked porous substrate was prepared via polymerization-induced phase separation. The PIM-1 TFC membranes were fabricated via a dip-coating procedure. Metallic ion-cross-linked PIM-1 TFC membranes were fabricated by hydrolyzing the PIM-1 TFC membrane in an alkali solution and then cross-linking it in a multivalent metallic ion solution. The pore size and porous structures were evaluated by low-temperature N_2 adsorption–desorption analysis. The membrane structure was investigated by field-emission scanning electron microscopy. The effects of heat treatment and pore-forming additives on the gas permeance of the UV-cross-linked porous substrate are reported. The effects of different pre-coating treatments on the gas permeance of the metallic ion-cross-linked PIM-1 TFC membrane are also discussed. The metallic ion-crosslinked PIM-1 TFC membrane displayed high CO_2/N_2 selectivity(23) and good CO_2 permeance(1058 GPU).
基金The study was supported by the COVID-19 Project of Shanxi Provincial Finance, and the Project of Shanxi Provincial Key Laboratory for major infectious disease response.
文摘Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (COVID-19) have a substantial burden on health-care systems around the world. This is a randomized parallel controlled trial for assessment of the immunogenicity and safety of an inactivated SARS-CoV-2 vaccine, aiming to determine an appropriate vaccination interval of the vaccine for high-risk occupational population.Methods: In an ongoing randomized, parallel, controlled phase IV trial between January and May 2021 in Taiyuan City, Shanxi Province, China, we randomly assigned the airport ground staff and public security officers aged 18 to 59 years to receive two doses of inactivated SARS-CoV-2 vaccine at 14 days, 21 days, or 28 days. The serum neutralizing antibody to live SARS-CoV-2 was performed at baseline and 28 days after immunization. Long-term data are being collected. The primary immunogenicity endpoints were neutralization antibody seroconversion and geometric mean titer (GMT) at 28 days after the second dose. Analysis of variance (ANOVA), chi-square, and logistic regression analysis were used for data analysis.Results: A total of 809 participants underwent randomization and received two doses of injections: 270, 270, 269 in the 0-14, 0-21, and 0-28 vaccination group, respectively. By day 28 after the second injection, SARS-CoV-2 neutralizing antibody of GMT was 98.4 (95%CI: 88.4-108.4) in the 0-14 group, which was significantly lower compared with 134.4 (95%CI: 123.1-145.7) in the 0-21 group (P < 0.001 vs 0-14 group) and 145.5 (95%CI: 131.3-159.6) in the 0-28 group (P < 0.001 vs 0-14 group), resulting in the seroconversion rates to neutralizing antibodies (GMT ≥ 16) of 100.0% for all three groups, respectively. The intention-to-treat (ITT) analysis yielded similar results. All reported adverse reactions were mild.Conclusions: Both a two-dose of inactivated SARS-CoV-2 vaccine at 0-21 days and 0-28 days regimens significantly improved SARS-CoV-2 neutralizing antibody level compared to the 0-14 days regimen in high-risk occupational population, with seroconversion rates of 100.0%.
